Navigation Links
Frost & Sullivan Recognizes Timoptic(R) (timolol maleate) as Best Brand Name Beta Blocker for Glaucoma: Timoptic Brand is Highest Rated in Survey of Ophthalmologists
Date:3/4/2010

LAWRENCEVILLE, N.J., March 4 /PRNewswire/ -- Aton Pharma, Inc., a diversified specialty pharmaceutical company, today announced that in an independent survey of U.S. ophthalmologists by Frost & Sullivan, Timoptic® was rated the leading brand name of beta blockers for glaucoma. Timoptic received Frost & Sullivan's 2010 Best Practices Award as the "Best Brand Name of Beta Blockers for Glaucoma," based on its Brand Perception Index (BPI) score, reflecting strong brand reputation, recognition and customer loyalty.

Provided by Aton Pharma, Timoptic (timolol maleate) is a non-selective, beta-adrenergic receptor blocking agent indicated for the treatment of elevated intraocular pressure (IOP) in patients with ocular hypertension or open-angle glaucoma.  

Frost & Sullivan surveyed 150 U.S. ophthalmologists using a web-based survey methodology during November 2009. In the survey, 50 percent of ophthalmologists ranked Timoptic as the #1 brand name of beta blockers – overwhelmingly above the nearest competitor. Overall, 54 percent of U.S. ophthalmologists surveyed use Timoptic as their primary beta blocker product for the treatment of glaucoma. Among those who use it, nearly all report Timoptic as one of the top three beta blockers for glaucoma.

"We are pleased that ophthalmologists recognize the Timoptic product line," stated Michael G. Wells, Chief Executive Officer of Aton Pharma.

"Based on its positive, strong brand reputation and high percentage of loyal ophthalmologist customers, Timoptic's Brand Perception Index (BPI) score qualified it as the 'Best Brand Name of Beta Blockers for Glaucoma'," commented Tonya M. Fowler, Frost & Sullivan's Global Director of Customer Research.

Aton CEO Wells added that the company is particularly pleased to build on Timoptic's reputation by providing Timoptic in Ocudose®, the only preservative-free medication for glaucoma available in the U.S. "With preservative-free Timoptic in Ocudose, Aton is able to enhance its mission of providing medically essential therapeutics that serve a critical role in the practice of medicine."

A preservative-free beta blocker is an important option for many glaucoma patients, who must use medication for long periods of time. Preservatives in glaucoma medications have been noted in the medical literature to cause some patients discomfort upon installation and may have toxic effects, compromising tear film stability and causing damage to the cornea and conjunctiva. This is a particular concern for those who already have dry eye, are at increased risk for ocular surface disease or are taking more than one prescribed medication for glaucoma.(1-3)

In an additional survey of ophthalmologists in March 2009 sponsored by Aton Pharma, virtually all (97%) believed preservative-free glaucoma medications may enhance the ocular comfort of glaucoma patients, while 86 percent believed that preservative-free glaucoma medications may enhance patient quality of life.  

About Timoptic

The U.S. Timoptic product line includes Timoptic (timolol maleate) Ophthalmic Solution, Timoptic (timolol maleate ophthalmic solution) in Ocudose® (sterile ophthalmic unit dose dispenser) and Timoptic-XE (timolol maleate ophthalmic gel forming solution) Ophthalmic. Timoptic in Ocudose is the only preservative-free medication for glaucoma available in the U.S. and aligns with Aton's strategy of providing unique, medically essential products.

Timoptic is indicated for the treatment of elevated intraocular pressure (IOP) in patients with ocular hypertension or open-angle glaucoma. Timoptic is contraindicated in patients with bronchial asthma; a history of bronchial asthma; severe chronic obstructive pulmonary disease; sinus bradycardia; second or third degree atrioventricular block; overt cardiac failure; cardiogenic shock; or hypersensitivity to any component of this product. Because of the potential effects of beta-adrenergic blocking agents on blood pressure and pulse, these agents should be used with caution in patients with cerebrovascular insufficiency. The same adverse reactions found with systemic administration of beta-adrenergic blocking agents may occur with topical ophthalmic administration. The most frequent adverse events have been burning and stinging upon installation. For more information, see www.ocudose.com.

About Frost & Sullivan Best Practices Awards

Frost & Sullivan Best Practice Awards recognize companies in a variety of regional and global markets for demonstrating outstanding achievement and superior performance in areas such as leadership, technological innovation, customer service, and strategic product development. Customer Research analysts conduct the survey research to identify best practices in the industry.

About Aton Pharma, Inc.

Aton Pharma, Inc., headquartered in Lawrenceville, NJ, is a global, diversified specialty pharmaceutical company providing essential treatments for under-treated diseases. Aton's mission is to improve patient outcomes and quality of life worldwide by enhancing and expanding access and availability of medically essential therapeutics. Aton's portfolio of products, with sales in over 30 countries, focuses on ophthalmic diseases and orphan conditions. For more information, see www.atonrx.com.

(1.) Baudouin C. The ocular surface in glaucoma, Cornea, Volume 28, Number 9, Suppl. 1, October 2009.

(2.) de Jong C, Stolwijk T, Kuppens E, et al. Topical timolol with and without benzalkonium chloride: epithelial permeability and autofluorescence of the cornea in glaucoma. Graefes Arch Clin Exp Ophthalmol. 1994;232: 221–224.

(3.) Jaenen N, Baudouin C, Pouliquen P, et al. Ocular symptoms and signs with preserved and preservative-free glaucoma medications. Eur J Ophthalmol. 2007;17:341–349.

SOURCE Aton Pharma, Inc.

Back to top

RELATED LINKS
http://www.ocudose.com
http://www.atonrx.com

'/>"/>

SOURCE Aton Pharma, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Frost & Sullivan: Western European Markets Confirm Undisputed Convenience and Cost Benefit of Custom Procedure Trays
2. Mennen Medical Receives Frost & Sullivan 2009 European Patient Monitoring Technology Leadership Award
3. Frost & Sullivan Lauds Viatronix as European Medical Imaging Emerging Company of the Year
4. Frost & Sullivan Identifies Focus on Quality Management and Adoption of a Full-service Model as Keys to the Growth of the European CRO Market
5. Widening Application Range to Boost MRI Markets in Eastern Europe, Says Frost & Sullivan
6. Lifesciences IT Spending to Experience Mature Growth Rates Despite Economic Slowdown, Declares Frost & Sullivan
7. Frost & Sullivan Recognizes Holst Centre and imec for Its Path Breaking Wearable Energy Harvester Technology
8. Frost & Sullivan Recognizes Japan Stent Technology for Its Pioneering Coronary Stent Design
9. Central and Eastern European Healthcare Markets Hold Strong Potential for Growth Despite the Economic Slowdown, Says Frost & Sullivan
10. Frost & Sullivan Recognizes Fovia for its HDVR(R) Platform - A Disruptive Technology Breakthrough
11. Frost & Sullivan Recognizes IntelligentMDx for Its Commitment to the Advancement of Healthcare and Diagnostics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... 23, 2016  Astellas today announced the establishment of Astellas Farma Colombia (AFC), a new affiliate with operations headquartered ... Latin America . ... ... ... ...
(Date:6/23/2016)... 2016  Guerbet announced today that it has been ... Award . One of 12 suppliers to ... its support of Premier members through exceptional local customer ... commitment to lower costs. ... our outstanding customer service from Premier," says Massimo ...
(Date:6/23/2016)... Research and Markets has announced ... Analysis (United States, China, Japan, Brazil, United Kingdom, Germany, ... offering. Surgical Procedure ... planners, provides surgical procedure volume data in a geographic ... in-depth analysis of growth drivers and inhibitors, including world ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... 2016 , ... PawPaws brand pet supplements owned by Whole Health ... the health of felines. The formula is all-natural and is made from Chinese herbs ... Cat Kidney Support Supplement Soft Chews are Astragalus Root Extract and Rehmannia ...
(Date:6/25/2016)... ... 25, 2016 , ... The temporary closing of Bruton Memorial Library on June 21 due to ... a new, often overlooked aspect of head lice: the parasite’s ability to live away from ... common occurrence, but a necessary one in the event that lice have simply gotten out ...
(Date:6/25/2016)... ... ... Friday, June 10, Van Mitchell, Secretary of the Maryland Department of Health and Mental ... exemplary accomplishments in worksite health promotion. , The Wellness at Work Awards took place ... BWI Marriott in Linthicum Heights. iHire was one of 42 businesses to receive an ...
(Date:6/24/2016)... ... ... crisis. Her son James, eight, was out of control. Prone to extreme mood shifts and ... him, he couldn’t control his emotions,” remembers Marcy. “If there was a knife on ... say he was going to kill them. If we were driving on the freeway, ...
(Date:6/24/2016)... ... ... BioMedics, Inc, makers of Topricin and MyPainAway Pain Relief Products, join The ‘Business for a ... an hour by 2020 and then adjusting it yearly to increase at the same rate ... assure the wage floor does not erode again, and make future increases more predictable. , ...
Breaking Medicine News(10 mins):